Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status:
Terminated
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
This will be a non-blinded, single arm study to test the efficacy of Regorafenib in patients
with recurrent ovarian, primary peritoneal, and fallopian tube cancer.